文献速递流行病学与生物统计临床试验与 GCP

平台试验中基于二分类结局的非同期对照贝叶斯幂先验:开发与比较评估

Bayesian Power Prior in Platform Trials With Non-Concurrent Control for Binary Outcomes: Development and Comparative Evaluation.
PubMed 文献 · Stat Med · 2026-01-01

该研究开发了一种新的贝叶斯幂先验方法,用于在二分类结局的平台试验中纳入非同期对照数据,通过数据驱动的相似性指数调整借用信息量以应对时间偏移。模拟研究比较了该方法与七种替代方法,在多种时间偏移场景下,该方法在控制I类错误(低于10%)与统计功效之间取得良好平衡,并应用于一项COVID-19平台试验数据。

要点

  • 新方法通过NCC与同期对照间的数据驱动相似性指数作为幂参数,实现自适应借用。
  • 模拟研究中,该方法在多种时间偏移场景下将I类错误率控制在10%以下,并避免过度借用。
  • 该方法在I类错误控制与统计功效之间取得良好平衡,并已应用于COVID-19平台试验数据。

核心结论

  • 所提出的贝叶斯幂先验方法在多种时间偏移场景下,在I类错误控制与统计功效之间持续取得良好平衡,将I类错误率维持在10%以下,并避免了更激进方法中出现的过度借用。

研究设计与样本

  • 研究开发了一种新的贝叶斯幂先验,用于在二分类结局的平台试验中纳入非同期对照数据。
  • 通过广泛模拟研究,将所提方法与七种替代方法进行比较:仅使用同期对照数据的分析、朴素合并方法、频率学派线性回归模型,以及四种旨在处理时间偏移的贝叶斯方法。
  • 将所提方法应用于一项涉及COVID-19患者的平台试验数据。

主要发现

  • 在多种时间偏移场景下,所提方法持续在I类错误控制与统计功效之间取得良好平衡,将I类错误率维持在10%以下,并避免了更激进方法中出现的过度借用。
  • 该方法通过非同期对照与同期对照数据之间的数据驱动相似性指数调整借用信息量,该指数作为幂先验中的幂参数,实现自适应借用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Platform trials enable the evaluation of multiple investigational drugs for a single disease and offer flexibility in adding or dropping treatments during the trial. This design would be advantageous for reducing the sample size and drug development time, particularly in contexts such as pandemics. In the platform trials, non-concurrent controls (NCCs) are often used for drug-control comparisons, but temporal shifts in subject characteristics, trial conduct, or standard of care can introduce bias in the estimation of treatment effects and increase the type I error rate. In this study, we develop a new Bayesian power prior to incorporate NCC data in platform trials with binary outcomes. To address temporal shifts, our method adjusts the amount of information borrowed from NCCs using a data-driven similarity index between NCC and concurrent control (CC) data. This index serves as the power parameter in the power prior, enabling adaptive borrowing. We evaluated the proposed method through extensive simulation studies, comparing its operating characteristics with seven alternatives: analysis using only CC data, naïve pooling method, a frequentist linear regression model, and four Bayesian methods designed to address temporal shifts. Across a range of temporal shift scenarios, the proposed method consistently achieved a favorable balance between type I error control and statistical power, maintaining type I error rates below 10% while avoiding the overborrowing seen in more aggressive methods. The practical utility of the proposed method was also examined by applying it to data from a platform trial involving patients with COVID-19.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Asano J, Sato H, Watanabe S, et al. Bayesian Power Prior in Platform Trials With Non-Concurrent Control for Binary Outcomes: Development and Comparative Evaluation. Stat Med. 2026. PMID: 41567103. doi:10.1002/sim.70387

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。